For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Survodutide

Also known as: BI 456906

Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).

Where to buy · live market data

Who's worth your money for Survodutide

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 9 scored sellers

$4.55/mg

$45.49 · 10mg · 99.0% purity

1 COA
Buy Code MERIT · 10% off

Best value

Lowest $/mg among scored sellers

$7.00/mg

$84.00 · 12mg · 99.9% purity

Most tested

2 independent COAs on file

$9.80/mg

$98.00 · 10mg · 99.9% purity

Average price

$21.65/mg

Sellers

22

45-day trend

+36.4%

13 of 22 sellers have a current price· 1 stale hidden· 3 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Survodutide

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Survodutide

CAS

2805997-46-8

Molecular formula

C192H289N47O61

Typical dose range

0.3–2.7 mg once weekly subcutaneous (clinical trials; Phase II/III dose-escalation)

Half-life

~6 days

Independent evidence

COAs for Survodutide

27 third-party tests across 10 vendors. Each card links to the full report.

All 27 COAs for Survodutide →
Measured purity 99.0%–99.9% across 17 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.00 %
Sep 2026
Ethos Analytics Strong

For

Survodutide

by Glacier Aminos· batch SUR10GA-01

Aggregated · 3rd-party listing
99.93 %
May 2026
Freedom Diagnostics Moderate

For

Survodutide

by Profound Aminos· batch Yellow Cap

Aggregated · 3rd-party listing
99.82 %
May 2026
Freedom Diagnostics Moderate

For

Survodutide

by Real Peptides· batch Clear Cap/Purple Crimp

Aggregated · 3rd-party listing
99.70 %
Jan 2026
Vanguard Laboratory Strong

For

Suvrodutide

by Kimera Chems· batch KC-SVD-BLK1

Aggregated · 3rd-party listing
99.77 %
Jan 2026
Freedom Diagnostics Moderate

For

Survodutide

by True Peptide· batch SURV-099-TPL

Aggregated · 3rd-party listing
99.76 %
Dec 2025
Janoshik Analytical Limited · HPLC

For

Survodutide

by Skye Peptides· batch SV25-12-001

✓ Vendor-published
99.88 %
Nov 2025
Janoshik Analytical Limited

For

Survodutide

by Ruo Bio· batch sur001

COA on file
Aggregated · 3rd-party listing
99.48 %
Nov 2025
Freedom Diagnostics Moderate

For

Survodutide

by Kimera Chems· batch KC-SVD-RED1

Aggregated · 3rd-party listing
99.41 %
Oct 2025
Vanguard Laboratory Strong

For

Survodutide

by Certified Peptides· batch SURVO10102125

Aggregated · 3rd-party listing
99.78 %
Oct 2025
Janoshik Analytical Limited · HPLC

For

Survodutide

by Skye Peptides· batch SV25-06-001

Aggregated · 3rd-party listing
99.44 %
Sep 2025
Janoshik Analytical Limited

For

Survodutide

by EZ Peptides· batch EZP-SURV1009082025-01

✓ Vendor-published
99.47 %
Sep 2025
Janoshik Analytical Limited

For

Survodutide

by EZ Peptides· batch EZP-SURV1009082025-01

COA on file
Aggregated · 3rd-party listing
99.78 %
Jan 2025
MZ Biolabs Moderate · HPLC

For

Survodutide

by Profound Aminos· batch 2025-01-23

Aggregated · 3rd-party listing
99.85 %
Sep 2024
MZ Biolabs Moderate · HPLC

For

Survodutide

by Hydro Research Peptides· batch 2024-08-05

Aggregated · 3rd-party listing
99.85 %
Sep 2024
MZ Biolabs Moderate

For

Survodutide

by Optima Supply· batch 2024-08-05

Aggregated · 3rd-party listing
99.47 %
Aug 2024
Janoshik Analytical Limited · HPLC

For

Survodutide

by Hydro Research Peptides· batch Survodutide-6028

Aggregated · 3rd-party listing
99.47 %
Aug 2024
Janoshik Analytical Limited

For

Survodutide

by Optima Supply· batch Survodutide-6033

Aggregated · 3rd-party listing
99.80 %
Vanguard Laboratory Strong

For

Survodutide

by Peptidology· batch 1671

Aggregated · 3rd-party listing
99.10 %
Vanguard Laboratory Strong

For

Suvrodutide

by Kimera Chems· batch KC-SVD-RED1

Aggregated · 3rd-party listing
—
Dec 2025

Purity not on file

Janoshik Analytical Limited

For

Survodutide

by Skye Peptides· batch SV25-12-001

Aggregated · 3rd-party listing
—
Dec 2025

Purity not on file

Janoshik Analytical Limited

For

Survodutide

by Skye Peptides· batch SV25-12-001

Aggregated · 3rd-party listing
—
Oct 2025

Purity not on file

Janoshik Analytical Limited

For

Survodutide

by Skye Peptides· batch SV25-06-001

Aggregated · 3rd-party listing
—
Oct 2025

Purity not on file

Janoshik Analytical Limited

For

Survodutide

by Skye Peptides· batch SV25-06-001

Aggregated · 3rd-party listing
—
Aug 2024

Purity not on file

Janoshik Analytical Limited

For

Survodutide

by Hydro Research Peptides· batch Survodutide-6028

Research depth

20 citations indexed for Survodutide

All research on Survodutide →

animal · 2026

Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease

Aims Survodutide is a novel long-acting dual glucagon (GCGR)/glucagon-like peptide-1 (GLP-1R) receptor agonist currently in phase-3 clinical development for the treatment of people living with obesity and metabolic dysfunction-associated steatohepatitis.

Study · 2026

Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties

Survodutide (BI 456906) is an investigational once-weekly dual glucagon and Glucagon-like Peptide (GLP-1) receptor agonist being developed for obesity.

Study · 2026

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes

Background For persons living with both type 2 diabetes and obesity, weight management may be the most effective therapy for type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have potent weight-reducing effects, and other mechanisms may confer additional benefits.

Study · 2026

Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN)

Introduction We aimed to describe the rationale, design, and overall baseline characteristics of the trial evaluating the efficacy, safety, and tolerability of survodutide in Chinese adults with overweight or obesity (SYNCHRONIZE™-CN, NCT06214741).

rct · 2026

Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

Aims This post hoc analysis evaluated the effect of survodutide on beta-cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations.

review · 2026

Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis

Recent therapeutic advances have resulted in US Food and Drug Administration (FDA) approval of the first pharmacological agents-resmetirom and semaglutide-for advanced metabolic dysfunction-associated steatohepatitis (MASH) without cirrhosis, reshaping the therapeutic landscape of the disease.